Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Intraperitoneal Treatment of Kisspeptin Suppresses Appetite and Energy Expenditure and Alters Gastrointestinal Hormones in Mice.

Dong TS, Vu JP, Oh S, Sanford D, Pisegna JR, Germano P.

Dig Dis Sci. 2019 Nov 15. doi: 10.1007/s10620-019-05950-7. [Epub ahead of print]

PMID:
31729619
2.

Novel Lipid Long Intervening Noncoding RNA, Oligodendrocyte Maturation-Associated Long Intergenic Noncoding RNA, Regulates the Liver Steatosis Gene Stearoyl-Coenzyme A Desaturase As an Enhancer RNA.

Benhammou JN, Ko A, Alvarez M, Kaikkonen MU, Rankin C, Garske KM, Padua D, Bhagat Y, Kaminska D, Kärjä V, Pihlajamäki J, Pisegna JR, Pajukanta P.

Hepatol Commun. 2019 Aug 14;3(10):1356-1372. doi: 10.1002/hep4.1413. eCollection 2019 Oct.

3.

Reverse gene-environment interaction approach to identify variants influencing body-mass index in humans.

Garske KM, Pan DZ, Miao Z, Bhagat YV, Comenho C, Robles CR, Benhammou JN, Alvarez M, Ko A, Ye CJ, Pisegna JR, Mohlke KL, Sinsheimer JS, Laakso M, Pajukanta P.

Nat Metab. 2019 Jun;1(6):630-642. doi: 10.1038/s42255-019-0071-6. Epub 2019 Jun 14.

4.

Baseline human gut microbiota profile in healthy people and standard reporting template.

King CH, Desai H, Sylvetsky AC, LoTempio J, Ayanyan S, Carrie J, Crandall KA, Fochtman BC, Gasparyan L, Gulzar N, Howell P, Issa N, Krampis K, Mishra L, Morizono H, Pisegna JR, Rao S, Ren Y, Simonyan V, Smith K, VedBrat S, Yao MD, Mazumder R.

PLoS One. 2019 Sep 11;14(9):e0206484. doi: 10.1371/journal.pone.0206484. eCollection 2019.

5.

Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data.

Baecker A, Kim S, Risch HA, Nuckols TK, Wu BU, Hendifar AE, Pandol SJ, Pisegna JR, Jeon CY.

PLoS One. 2019 Jun 25;14(6):e0218580. doi: 10.1371/journal.pone.0218580. eCollection 2019.

6.

Magnetic resonance imaging as a non-invasive method for the assessment of pancreatic fibrosis (MINIMAP): a comprehensive study design from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer.

Tirkes T, Yadav D, Conwell DL, Territo PR, Zhao X, Venkatesh SK, Kolipaka A, Li L, Pisegna JR, Pandol SJ, Park WG, Topazian M, Serrano J, Fogel EL; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Abdom Radiol (NY). 2019 Aug;44(8):2809-2821. doi: 10.1007/s00261-019-02049-5.

PMID:
31089778
7.

Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant.

Jacob N, Dasharathy SS, Bui V, Benhammou JN, Grody WW, Singh RR, Pisegna JR.

Dig Dis Sci. 2019 Aug;64(8):2140-2146. doi: 10.1007/s10620-019-05525-6. Epub 2019 Feb 20.

PMID:
30788684
8.

An Intraperitoneal Treatment with Calcitonin Gene-Related Peptide (CGRP) Regulates Appetite, Energy Intake/Expenditure, and Metabolism.

Sanford D, Luong L, Gabalski A, Oh S, Vu JP, Pisegna JR, Germano P.

J Mol Neurosci. 2019 Jan;67(1):28-37. doi: 10.1007/s12031-018-1202-3. Epub 2018 Dec 10.

9.

A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.

Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, Donahue TR, Hines OJ, Reber HA, Dawson DW, Tomlinson JS.

J Gastrointest Surg. 2019 Jul;23(7):1392-1400. doi: 10.1007/s11605-018-4011-7. Epub 2018 Oct 23.

10.

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c.

Dong TS, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR.

World J Hepatol. 2018 Sep 27;10(9):612-621. doi: 10.4254/wjh.v10.i9.612.

11.

Prevalence of Panoramically Imaged Carotid Atheromas in Alcoholic Patients With Chronic Pancreatitis and Comorbid Diabetes.

Lee UK, Chang TI, Polanco JC, Pisegna JR, Friedlander AH.

J Oral Maxillofac Surg. 2018 Sep;76(9):1929.e1-1929.e7. doi: 10.1016/j.joms.2018.05.011. Epub 2018 May 15.

12.

Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Mohapatra SS, Batra SK, Bharadwaj S, Bouvet M, Cosman B, Goel A, Jogunoori W, Kelley MJ, Mishra L, Mishra B, Mohapatra S, Patel B, Pisegna JR, Raufman JP, Rao S, Roy H, Scheuner M, Singh S, Vidyarthi G, White J.

Dig Dis Sci. 2018 May;63(5):1123-1138. doi: 10.1007/s10620-018-5000-0. Epub 2018 Mar 23. Review.

13.

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.

Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, Dixit V, Bhattacharya D, Han SB, Pisegna JR.

Pharmacol Res Perspect. 2018 Feb 22;6(2):e00379. doi: 10.1002/prp2.379. eCollection 2018 Apr.

14.

Impact of sustained virologic response on chronic kidney disease progression in hepatitis C.

Aby ES, Dong TS, Kawamoto J, Pisegna JR, Benhammou JN.

World J Hepatol. 2017 Dec 28;9(36):1352-1360. doi: 10.4254/wjh.v9.i36.1352.

15.

Long-Term Intake of a High-Protein Diet Affects Body Phenotype, Metabolism, and Plasma Hormones in Mice.

Vu JP, Luong L, Parsons WF, Oh S, Sanford D, Gabalski A, Lighton JR, Pisegna JR, Germano PM.

J Nutr. 2017 Dec;147(12):2243-2251. doi: 10.3945/jn.117.257873. Epub 2017 Oct 25.

16.

Gastrointestinal Manifestations of Hereditary Hemorrhagic Telangiectasia (HHT): A Systematic Review of the Literature.

Jackson SB, Villano NP, Benhammou JN, Lewis M, Pisegna JR, Padua D.

Dig Dis Sci. 2017 Oct;62(10):2623-2630. doi: 10.1007/s10620-017-4719-3. Epub 2017 Aug 23. Review.

17.

The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors.

Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR.

Curr Gastroenterol Rep. 2017 Aug;19(8):42. doi: 10.1007/s11894-017-0577-6. Review.

18.

High-protein diet improves sensitivity to cholecystokinin and shifts the cecal microbiome without altering brain inflammation in diet-induced obesity in rats.

Wang L, Jacobs JP, Lagishetty V, Yuan PQ, Wu SV, Million M, Reeve JR Jr, Pisegna JR, Taché Y.

Am J Physiol Regul Integr Comp Physiol. 2017 Oct 1;313(4):R473-R486. doi: 10.1152/ajpregu.00105.2017. Epub 2017 Jul 19.

19.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K.

J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450. Epub 2017 May 4.

20.

Autoimmune atrophic gastritis: current perspectives.

Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR.

Clin Exp Gastroenterol. 2017 Feb 7;10:19-27. doi: 10.2147/CEG.S109123. eCollection 2017. Review.

21.

Endoscopic Ultrasound-Guided Fine Needle Aspiration Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared To Computer Tomography-Guided Fine Needle Aspiration.

Wang J, Benhammou JN, Ghassemi K, Kim S, Sedarat A, Farrell J, Pisegna JR.

J Gastroenterol Pancreatol Liver Disord. 2017;4(2):1-7. doi: 10.15226/2374-815X/4/2/00186. Epub 2017 Mar 27.

22.

A Sodium Channel Myotonia Presenting with Intermittent Dysphagia as a Manifestation of a Rare SCN4A Variant.

Benhammou JN, Phan J, Lee H, Ghassemi K, Parsons W, Grody WW, Pisegna JR.

J Mol Neurosci. 2017 Mar;61(3):312-314. doi: 10.1007/s12031-016-0878-5. Epub 2016 Dec 23.

23.

A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation.

Padua D, Mahurkar-Joshi S, Law IK, Polytarchou C, Vu JP, Pisegna JR, Shih D, Iliopoulos D, Pothoulakis C.

Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G446-57. doi: 10.1152/ajpgi.00212.2016. Epub 2016 Aug 4.

24.

The Role of Neuropeptides in Mouse Models of Colitis.

Padua D, Vu JP, Germano PM, Pisegna JR.

J Mol Neurosci. 2016 Jun;59(2):203-10. doi: 10.1007/s12031-015-0688-1. Epub 2015 Dec 8. Review.

25.

Gastric Hypersecretory States: Investigation and Management.

Phan J, Benhammou JN, Pisegna JR.

Curr Treat Options Gastroenterol. 2015 Dec;13(4):386-97. doi: 10.1007/s11938-015-0065-8.

26.

PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin.

Vu JP, Goyal D, Luong L, Oh S, Sandhu R, Norris J, Parsons W, Pisegna JR, Germano PM.

Am J Physiol Gastrointest Liver Physiol. 2015 Nov 15;309(10):G816-25. doi: 10.1152/ajpgi.00190.2015. Epub 2015 Sep 3.

27.

Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP).

Vu JP, Larauche M, Flores M, Luong L, Norris J, Oh S, Liang LJ, Waschek J, Pisegna JR, Germano PM.

J Mol Neurosci. 2015 Jun;56(2):377-87. doi: 10.1007/s12031-015-0556-z. Epub 2015 Apr 23.

28.

Inhibition of vasoactive intestinal polypeptide (VIP) induces resistance to dextran sodium sulfate (DSS)-induced colitis in mice.

Vu JP, Million M, Larauche M, Luong L, Norris J, Waschek JA, Pothoulakis C, Pisegna JR, Germano PM.

J Mol Neurosci. 2014 Jan;52(1):37-47. doi: 10.1007/s12031-013-0205-3. Epub 2014 Jan 7.

29.

High-protein diet selectively reduces fat mass and improves glucose tolerance in Western-type diet-induced obese rats.

Stengel A, Goebel-Stengel M, Wang L, Hu E, Karasawa H, Pisegna JR, Taché Y.

Am J Physiol Regul Integr Comp Physiol. 2013 Sep 15;305(6):R582-91. doi: 10.1152/ajpregu.00598.2012. Epub 2013 Jul 24.

30.

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI.

Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x. Review.

31.

Ghrelin in neuroendocrine tumors.

Vu JP, Wang HS, Germano PM, Pisegna JR.

Peptides. 2011 Nov;32(11):2340-7. doi: 10.1016/j.peptides.2011.10.006. Epub 2011 Oct 29. Review.

32.

Clinical trial report: Eradication of Helicobacter pylori reduces the risk for subsequent gastric cancer.

Pisegna JR, Surti B, Scott DR.

Curr Gastroenterol Rep. 2010 Dec;12(6):427-30. doi: 10.1007/s11894-010-0138-8. No abstract available.

33.

PAC1 deficiency in a murine model induces gastric mucosa hypertrophy and higher basal gastric acid output.

Lu Y, Germano P, Ohning GV, Vu JP, Pisegna JR.

J Mol Neurosci. 2011 Jan;43(1):76-84. doi: 10.1007/s12031-010-9440-z. Epub 2010 Sep 4.

34.

Do COX-2 inhibitors reduce metachronous cancer development?

Pisegna JR.

Curr Gastroenterol Rep. 2009 Dec;11(6):429-30. No abstract available.

PMID:
19903417
35.

PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.

Germano PM, Lieu SN, Xue J, Cooke HJ, Christofi FL, Lu Y, Pisegna JR.

J Mol Neurosci. 2009 Nov;39(3):391-401. doi: 10.1007/s12031-009-9283-7. Epub 2009 Aug 23.

36.

Duodenal bulb mucosa with hypertrophic gastric oxyntic heterotopia in patients with zollinger ellison syndrome.

Kohan E, Oh D, Wang H, Hazany S, Ohning G, Pisegna JR.

Diagn Ther Endosc. 2009;2009:298381. doi: 10.1155/2009/298381. Epub 2009 Jul 1.

37.

Is surveillance upper endoscopy indicated for gastric ulcers?

Pisegna JR.

Curr Gastroenterol Rep. 2008 Dec;10(6):521-2. No abstract available.

PMID:
19006604
38.

Effect of preoperative intravenous pantoprazole in elective-surgery patients: a pilot study.

Pisegna JR, Karlstadt RG, Norton JA, Fogel R, Oh DS, Jay Graepel G, Dorr MB.

Dig Dis Sci. 2009 May;54(5):1041-9. doi: 10.1007/s10620-008-0445-1. Epub 2008 Aug 27.

39.

Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Wang HS, Oh DS, Anderson A, Nieto J, Tien P, Ohning G, Pisegna JR.

Gut Liver. 2008 Jun;2(1):30-8. doi: 10.5009/gnl.2008.2.1.30. Epub 2008 Jun 30.

40.

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.

Pisegna JR, Sostek MB, Monyak JT, Miner PB Jr.

Aliment Pharmacol Ther. 2008 Mar 15;27(6):483-90. Epub 2007 Dec 19.

41.
42.

Pituitary adenylate cyclase-activating polypeptide: a novel peptide with protean implications.

Pisegna JR, Oh DS.

Curr Opin Endocrinol Diabetes Obes. 2007 Feb;14(1):58-62. Review.

43.

Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.

Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR.

Am J Gastroenterol. 2007 Dec;102(12):2648-54. Epub 2007 Aug 31.

PMID:
17764495
44.

Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease.

Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA.

Peptides. 2007 Sep;28(9):1688-99. Epub 2007 May 18.

45.
46.

Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome.

Oh DS, Wang HS, Ohning GV, Pisegna JR.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1467-73. Epub 2006 Nov 13.

47.

Neuroendocrine tumors express PAC1 receptors.

Lieu SN, Oh DS, Pisegna JR, Germano PM.

Ann N Y Acad Sci. 2006 Jul;1070:399-404.

48.

The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome.

Nieto JM, Pisegna JR.

Expert Opin Pharmacother. 2006 Feb;7(2):169-75. Review.

PMID:
16433582
49.

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, Pisegna JR.

Aliment Pharmacol Ther. 2006 Feb 1;23(3):437-44.

50.

PACAP regulation of secretion and proliferation of pure populations of gastric ECL cells.

Oh DS, Lieu SN, Yamaguchi DJ, Tachiki K, Lambrecht N, Ohning GV, Sachs G, Germano PM, Pisegna JR.

J Mol Neurosci. 2005;26(1):85-97.

Supplemental Content

Loading ...
Support Center